Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis
Open Access
- 1 June 2020
- journal article
- research article
- Published by Elsevier BV in Gastroenterology
- Vol. 158 (8), 2139-+
- https://doi.org/10.1053/j.gastro.2020.02.030
Abstract
No abstract availableFunding Information
- Atlantic Healthcare Limited
- Amgen
- Genentech
- Gilead Sciences
- AbbVie
- Janssen
- Takeda
- Lilly
- Celgene
- Receptos
- Pfizer
- Prometheus Laboratories
This publication has 33 references indexed in Scilit:
- Self-reported Symptom Burden in Individuals with Inflammatory Bowel DiseaseJournal of Crohn's and Colitis, 2015
- Development and validation of a histological index for UCGut, 2015
- Segundo Consenso Europeo basado en evidencia sobre el diagnóstico y tratamiento de la colitis ulcerosa crónica idiopática Parte 1: Definiciones y diagnóstico (versión española)Revista de Gastroenterologia de Mexico, 2014
- A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s DiseaseClinical Gastroenterology and Hepatology, 2014
- Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid ArthritisArthritis & Rheumatology, 2014
- Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension StudiesThe Journal of Rheumatology, 2014
- Venous thromboembolism in patients with inflammatory bowel disease: Focus on prevention and treatmentWorld Journal of Gastroenterology, 2014
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative ColitisThe New England Journal of Medicine, 2013
- Ulcerative colitisThe Lancet, 2012
- Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort studyThe Lancet, 2010